Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?

被引：4

作者：

Boccia, Serena Maria ^{[1
]}

Sassu, Carolina Maria ^{[1
]}

Ergasti, Raffaella ^{[1
]}

Vertechy, Laura ^{[1
]}

Apostol, Adriana Ionelia ^{[2
]}

Palluzzi, Eleonora ^{[1
]}

Fagotti, Anna ^{[1
,2
]}

Scambia, Giovanni ^{[1
,2
]}

Marchetti, Claudia ^{[1
,2
]}

机构：

[1] Fdn Policlin Univ Agostino Gemelli, IRCCS, Dipartimento Sci Salute Donna Bambino & Sanita Pub, I-00136 Rome, Italy

[2] Univ Cattolica Sacro Cuore, Dipartimento Sci Vita & Sanita Pubbl, I-00136 Rome, Italy

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2024年 / 18卷

关键词：

ovarian cancer; trabectedin; platinum eligibility; PEGYLATED LIPOSOMAL DOXORUBICIN; HYPERSENSITIVITY REACTIONS; ECTEINASCIDIN-743; MECHANISM; ANTITUMOR; EFFICACY; ET-743; TRIAL; BEVACIZUMAB; COMBINATION;

D O I：

10.2147/DDDT.S451223

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In the era of single and combination maintenance therapies as well as platinum and Poly (ADP-ribose) polymerase inhibitors (PARPi) resistance, the choice of subsequent treatments following first-line platinum-based chemotherapy in recurrent ovarian cancer (ROC) patients has become increasingly complex. Within the ovarian cancer treatment algorithm, particularly in the emerging context of PARPi resistance, the role of trabectedin, in combination with pegylated liposomal doxorubicin (PLD) still preserves its significance. This paper offers valuable insights into the multifaceted role and mechanism of action of trabectedin in ROC. The main results of clinical trials and studies involving trabectedin/PLD, along with hints of Breast Cancer genes (BRCA)mutated and BRCAness phenotype cases, are critically discussed. Moreover, this review provides and contextualizes potential scenarios of administering trabectedin in combination with PLD in ROC, according to established guidelines and beyond.

引用

页码：2021 / 2032

页数：12

共 51 条

[1] Von Hippel-Lindau - Coupled and Transcription-Coupled Nucleotide Excision Repair - Dependent Degradation of RNA Polymerase 11 in Response to Trabectendin [J].

Aune, Gregory J. ;

Takagi, Kazutaka ;

Sordet, Olivier ;

Guirouilh-Barbat, Josee ;

Antony, Smitha ;

Bohr, Vilhelm A. ;

Pommier, Yves .

CLINICAL CANCER RESEARCH, 2008, 14 (20) :6449-6455

[2] Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Banerjee, Susana ;

Moore, Kathleen N. ;

Colombo, Nicoletta ;

Scambia, Giovanni ;

Kim, Byoung-Gie ;

Oaknin, Ana ;

Friedlander, Michael ;

Lisyanskaya, Alla ;

Floquet, Anne ;

Leary, Alexandra ;

Sonke, Gabe S. ;

Gourley, Charlie ;

Oza, Amit ;

Gonzalez-Martin, Antonio ;

Aghajanian, Carol ;

Bradley, William H. ;

Holmes, Eileen ;

Lowe, Elizabeth S. ;

DiSilvestro, Paul .

LANCET ONCOLOGY, 2021, 22 (12) :1721-1731

[3] Tumor-associated macrophages and anti-tumor therapies: complex links [J].

Belgiovine, Cristina ;

D'Incalci, Maurizio ;

Allavena, Paola ;

Frapolli, Roberta .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2016, 73 (13) :2411-2424

[4]

Bonfanti M, 1999, ANTI-CANCER DRUG DES, V14, P179

[5] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].

Burger, Robert A. ;

Brady, Mark F. ;

Bookman, Michael A. ;

Fleming, Gini F. ;

Monk, Bradley J. ;

Huang, Helen ;

Mannel, Robert S. ;

Homesley, Howard D. ;

Fowler, Jeffrey ;

Greer, Benjamin E. ;

Boente, Matthew ;

Birrer, Michael J. ;

Liang, Sharon X. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483

[6] Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2 [J].

Cohen, Sharon ;

Bruchim, Ilan ;

Graiver, Dror ;

Evron, Zoharia ;

Oron-Karni, Varda ;

Pasmanik-Chor, Metsada ;

Eitan, Ram ;

Bernheim, Joelle ;

Levavi, Hanoch ;

Fishman, Ami ;

Flescher, Eliezer .

JOURNAL OF MOLECULAR MEDICINE-JMM, 2013, 91 (03) :357-368

[7] Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin [J].

Colmegna, B. ;

Uboldi, S. ;

Frapolli, R. ;

Licandro, S. A. ;

Panini, N. ;

Galmarini, C. M. ;

Badri, Nadia ;

Spanswick, V. J. ;

Bingham, J. P. ;

Kiakos, Konstantinos ;

Erba, E. ;

Hartley, J. A. ;

D'Incalci, M. .

BRITISH JOURNAL OF CANCER, 2015, 113 (12) :1687-1693

[8] INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line [J].

Colombo, N. ;

Gadducci, A. ;

Sehouli, J. ;

Rulli, E. ;

Maenpaa, J. ;

Sessa, C. ;

Montes, A. ;

Ottevanger, N. B. ;

Berger, R. ;

Vergote, I. ;

D'Incalci, M. ;

Galaz, C. Churruca ;

Chekerov, R. ;

Nyvang, G. B. ;

Riniker, S. ;

Herbertson, R. ;

Fossati, R. ;

Barretina-Ginesta, M. P. ;

Deryal, M. ;

Mirza, M. R. ;

Biagioli, E. ;

Iglesias, M. ;

Funari, G. ;

Romeo, M. ;

Tasca, G. ;

Pardo, B. ;

Tognon, G. ;

Rubio-Perez, M. J. ;

DeCensi, A. ;

De Giorgi, U. ;

Zola, P. ;

Panici, P. Benedetti ;

Aglietta, M. ;

Arcangeli, V. ;

Zamagni, C. ;

Bologna, A. ;

Westermann, A. ;

Heinzelmann-Schwarz, V. ;

Tsibulak, I. ;

Wimberger, P. ;

Poveda, A. .

BRITISH JOURNAL OF CANCER, 2023, 128 (08) :1503-1513

[9] Trabectedin plus pegylated liposomal doxorubicin (PLD) prior to subsequent platinum chemotherapy in patients with platinum-resistant (PR) recurrent ovarian cancer (ROC): Results from OVA-301 follow-up. [J].

Colombo, Nicoletta ;

Casado, Antonio ;

Fernandez, Consuelo ;

Vergote, Ignace .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[10] The role of interleukin-6 in gynaecological malignancies [J].

Coward, Jermaine I. G. ;

Kulbe, Hagen .

CYTOKINE & GROWTH FACTOR REVIEWS, 2012, 23 (06) :333-342

← 1 2 3 4 5 6 →